Showing results (1-10 of 46) with videos related to
Sort By:
Pageof 5
Journal of Cardiovascular Pharmacology|December 20, 2007
Mechanisms of ET-1-induced endothelial dysfunctionMarc Iglarz, Martine ClozelClinical Science (London, England : 1979)|August 18, 2010
At the heart of tissue: endothelin system and end-organ damageMarc Iglarz, Martine ClozelCurrent Hypertension Reports|March 19, 2003
Role of endothelin-1 in hypertensionMarc Iglarz, Ernesto L SchiffrinThe Journal of Pharmacology and Experimental Therapeutics|March 29, 2018
Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral ArteryKeith Morrison, Franck Haag, Roland Ernst, et al.Journal of Hypertension|January 22, 2005
Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesisPierre Beaucage, Marc Iglarz, Marc Servant, et al.Current Hypertension Reports|January 16, 2002
Genetic determinants of vascular reactivityDaniel Henrion, Joelle Benessiano, Marc Iglarz, et al.Journal of Cardiovascular Pharmacology|May 21, 2015
Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB ReceptorsMarc Iglarz, Pauline Steiner, Daniel Wanner, et al.Hypertension (Dallas, Tex. : 1979)|July 23, 2003
Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertensionErnesto L Schiffrin, Farhad Amiri, Karim Benkirane, et al.Experimental Biology and Medicine (Maywood, N.J.)|June 3, 2006
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in ratsMartine Clozel, Patrick Hess, Markus Rey, et al.Life Sciences|March 16, 2016
Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic miceMartin Houde, Louisane Desbiens, Adel Schwertani, et al.Pageof 5